Journal of Clinical Endocrinology & Metabolism, Vol 64, 1136-1141, Copyright © 1987 by Endocrine Society

ARTICLES

Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man

ML Vance, DL Kaiser, LA Frohman, J Rivier, WW Vale and MO Thorner

The role of the dopaminergic system and its interaction with GH- releasing hormone (GHRH) in the regulation of GH secretion was investigated in normal men in two complementary studies. The men were given continuous iv infusions of 0.15 M saline (5 h), dopamine (4 micrograms/kg X min; 1 h), GHRH (2 ng/kg X min; 2 h), and GHRH (2 ng/kg X min; 2 h) plus dopamine (4 micrograms/kg X min; 1 h) on four separate occasions, and serum GH responses were measured. In a second study, on separate days, placebo or bromocriptine (2.5 mg/dose) was administered, and GH and PRL responses to a single iv GHRH dose were measured. A continuous infusion of dopamine and GHRH on separate days stimulated GH secretion in all subjects. The mean integrated GH secretion was 13.2 +/- 3.1 (+/- SEM) ng/mL X h during the dopamine infusion and 14.7 +/- 4.6 during GHRH, compared with 1.7 +/- 0.4 during the saline infusion. The combination of GHRH and dopamine resulted in the greatest stimulation of GH secretion (29.8 +/- 5.7 ng/ml X h; P less than 0.05 vs. 3 other study days). The oral dopamine agonist bromocriptine also augmented GHRH-stimulated GH secretion. Integrated GH secretion after a single iv injection of GHRH following two doses of bromocriptine was 160 +/- 29.5 ng/ml X h compared with 81.3 +/- 22.2 after placebo (P = 0.04). We suggest that these findings are compatible with the hypothesis that dopamine inhibits hypothalamic somatostatin secretion, which then allows for a greater stimulatory effect of GHRH.

This article has been cited by other articles:

				E. R. Samuels, R. H. Hou, R. W. Langley, E. Szabadi, and C. M. Bradshaw Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers J Psychopharmacol, November 1, 2006; 20(6): 756 - 770. [Abstract] [PDF]

				A. Wieck, R. A. Davies, A. D. Hirst, N. Brown, A. Papadopoulos, M. N. Marks, S. A. Checkley, R. C. Kumar, and I. C. Campbell Menstrual Cycle Effects on Hypothalamic Dopamine Receptor Function in Women with a History of Puerperal Bipolar Disorder J Psychopharmacol, June 1, 2003; 17(2): 204 - 209. [Abstract] [PDF]

				J.S. Cunha-Filho, J.L. Gross, N.A. Lemos, E.C. Dias, D. Vettori, C.A. Souza, and E.P. Passos Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis Hum. Reprod., April 1, 2002; 17(4): 960 - 965. [Abstract] [Full Text] [PDF]

				M F P Peres, M S. del Rio, M L V Seabra, S Tufik, J Abucham, J Cipolla-Neto, S D Silberstein, and E Zukerman Hypothalamic involvement in chronic migraine J. Neurol. Neurosurg. Psychiatry, December 1, 2001; 71(6): 747 - 751. [Abstract] [Full Text] [PDF]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]